Golidocitinib plus CHOP for new T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have been diagnosed with a type of T-cell lymphoma that is not NK/T-cell lymphoma.
- You have at least one tumor that can be measured on a CT scan (a lymph node >1.5 cm or other tumor >1 cm).
- Your blood counts, liver, kidney, and heart function are good enough for the study.
- You have not had a heart attack, unstable angina, heart failure, or major heart rhythm problems in the last 6 months.
- You do not have lymphoma that has spread to your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This Phase 2 trial tests how well Go-CHOP works as the first treatment for peripheral T-cell lymphoma (PTCL) subtypes. It aims to see whether adding golidocitinib to standard chemotherapy can control the lymphoma and improve outcomes.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
This trial is testing a combination of two targeted drugs – chidamide (an HDAC inhibitor) and golidocitinib (a JAK inhibitor) – for people with peripheral T-cell lymphoma that has come back or hasn't responded to prior treatments. The goal is to see if this combination can shrink tumors or stop the cancer from growing.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.